Falecalcitriol controlled-release tablet

Abstract

The invention provides a preparation method of a falecalcitriol controlled-release tablet, and belongs to the technical field of medicines. The falecalcitriol controlled-release preparation in the invention is composed of a tablet containing core and a coating film wrapping the tablet containing core; the tablet containing core comprises falecalcitriol, a filler and sodium chloride; the coating film comprises a controlled-release material, a plasticizer and a pore-foaming agent; when preparation, the tablet containing core is wrapped by the coating film, wherein the main component, namely falecalcitriol, belongs to the vitamin D3 analogue, can adjust calcium metabolism and resist rickets, and can be used for treating hypoparathyroidism. The drug in the invention can be released slowly anduniformly; the purposes of being long to act and increasing the curative effect are achieved; the dosage also can be reduced when the same drug effect is kept; therefore, side effects of taking drugsto patients are reduced; furthermore, the preparation process is simple; and the obtained product is steady in quality and suitable for large-scale production and application.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a preparation method of flucitriol controlled-release tablets. The invention provides a safe, effective, stable quality, low cost, less frequency of administration, enhanced patient compliance, and stable pain relief. Controlled-release preparations for spasms. Background technique [0002] Calcitriol is an analogue of vitamin D3 and a derivative of the active form of the small intestine. It plays a role by binding to receptors distributed in target tissues. This product can regulate calcium metabolism and resist rickets. It is used for the treatment of parathyroid function Hypoplasia. Existing calcitriol preparations are mainly tablets, and calcitriol tablets were jointly developed and marketed by Sumitomo and Taisho Pharmaceutical in Japan at the earliest in April 2001; they are not listed in other countries. [0003] The parathyroid glands are endocrine glands mostly located ...

AI Technical Summary

Problems solved by technology

[0006] In order to solve the disadvantages of inconvenient taking and low bioavailability of the existing fluorocalciotriol preparations, the present invention invented fluorocalciotriol controlled-release tablets, which can reduce the number of times of taking medicine, slow down the absorption rate, prolong the biological half-life, and control the blood drug concentration at Within the effective blood concentration range, thereby reducing side effects and improving patient compliance

Images